Core Laboratories (NYSE:CLB) Given Sell (D+) Rating at Weiss Ratings

Key Points

• Core Laboratories has been given a "sell (D+)" rating by Weiss Ratings, while other analysts have varied their ratings from "sell" to "hold".
• Core Laboratories' stock price recently increased by 1.4%, trading at $12.09, with a market cap of $566.90 million.
• During its last earnings report, the company reported $0.19 EPS, exceeding estimates, but revenues declined by 0.3% compared to the prior year.

Core Laboratories (NYSE:CLB - Get Free Report)'s stock had its "sell (d+)" rating reissued by equities research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other research analysts also recently weighed in on the stock. Wall Street Zen raised shares of Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Zacks Research raised shares of Core Laboratories from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Finally, Stifel Nicolaus cut their price target on shares of Core Laboratories from $13.00 to $12.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $12.50.

Core Laboratories Stock Up 1.4%

Shares of CLB stock traded up $0.17 during trading hours on Wednesday, hitting $12.09. 278,286 shares of the company were exchanged, compared to its average volume of 496,631. The business has a 50 day moving average of $11.60 and a two-hundred day moving average of $11.97. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.47. Core Laboratories has a 52 week low of $9.72 and a 52 week high of $21.83. The company has a market capitalization of $566.90 million, a PE ratio of 19.50, a PEG ratio of 3.60 and a beta of 1.38.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.01. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The company had revenue of $130.16 million during the quarter, compared to the consensus estimate of $129.19 million. During the same quarter in the prior year, the firm earned $0.22 earnings per share. The firm's revenue was down .3% compared to the same quarter last year. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. Analysts anticipate that Core Laboratories will post 0.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in shares of Core Laboratories by 972.6% in the first quarter. GAMMA Investing LLC now owns 68,669 shares of the oil and gas company's stock valued at $1,029,000 after purchasing an additional 62,267 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Core Laboratories by 1.7% in the first quarter. Rhumbline Advisers now owns 138,610 shares of the oil and gas company's stock valued at $2,078,000 after acquiring an additional 2,376 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Core Laboratories by 19.8% in the first quarter. Oppenheimer Asset Management Inc. now owns 69,184 shares of the oil and gas company's stock valued at $1,037,000 after acquiring an additional 11,438 shares during the period. Principal Financial Group Inc. lifted its position in Core Laboratories by 2.1% during the first quarter. Principal Financial Group Inc. now owns 233,829 shares of the oil and gas company's stock valued at $3,505,000 after purchasing an additional 4,733 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in Core Laboratories by 1.3% during the first quarter. Envestnet Asset Management Inc. now owns 254,005 shares of the oil and gas company's stock valued at $3,808,000 after purchasing an additional 3,357 shares during the last quarter. Institutional investors and hedge funds own 97.81% of the company's stock.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.